CI
EGRX

CX Institutional’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

CX Institutional’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-100
Closed -$6K – 797
2019
Q4 		$6K Hold
100
– – ﹤0.01% 530
2019
Q3 		$6K Buy
+100
New +$5.62K ﹤0.01% 560
2019
Q2 		– Sell
-100
Closed -$5K – 1001
2019
Q1 		$5K Hold
100
– – ﹤0.01% 563
2018
Q4 		$4K Hold
100
– – ﹤0.01% 413
2018
Q3 		$7K Hold
100
– – ﹤0.01% 281
2018
Q2 		$8K Buy
+100
New +$6.29K ﹤0.01% 247

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CX Institutional's EGRX Position: Q1 2020 in Review

CX Institutional sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2020, closing a stake of 100 shares — an estimated $6K sold.

CX Institutional first reported a position in EGRX in Q2 2018 and held it in 6 quarters. The position peaked at $8K in Q2 2018. 168 funds tracked by Wall St. Rank hold EGRX as of Q1 2020.

  • CX Institutional reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • CX Institutional sold 100 Eagle Pharmaceuticals, Inc. shares in Q1 2020, an estimated $6K.
  • CX Institutional first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2018 and held it in 6 quarters.
  • CX Institutional's Eagle Pharmaceuticals, Inc. position peaked at $8K in Q2 2018.
  • 168 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2020.

Based on CX Institutional's 13F filing for Q1 2020, filed 29 Apr 2020.